Drugs / Repaircell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01739530 | Mar → Nov 2009 | — | Anterogen Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Repaircell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01739530 ↗ |
| Modality | Cell therapy | “Allogenic differentiated adipocytes (ANT-adip-AL)” NCT01739530 ↗ |
| Route | Subcutaneous | “Subjects were received subcutaneous injection of ANT-adip-AL” NCT01739530 ↗ |